Gerard Oghlakian, MD
Basic profileAdvanced Heart Failure and Transplant Cardiology
Gerard Oghlakian is a Cardiology physician. OpenAlex indexes 16 publications with 371 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2115 S Fremont Ave
Ste 4300
Springfield, MO 658042239
Telephone
417-820-3911Registry record last updated 28 Nov 2017.
Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202516 payments$42,323openpaymentsdata.cms.gov ↗
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year202516 payments$23,550openpaymentsdata.cms.gov ↗
- Lilly USA, LLCProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
73.7%Beta blocker16.4%Metoprolol Succinate54%Carvedilol29%Metoprolol Tartrate16%Atenolol2%Part D<11 patientsStatin13.1%Atorvastatin Calcium71%Rosuvastatin Calcium25%Pravastatin Sodium4%Part D<11 patients+ 16 more classes in this area
Blood & clotting
16%Factor Xa inhibitor10.9%Eliquis83%Xarelto17%Part D≥87 patientsVitamin K antagonist3.1%Warfarin Sodium100%Part D≥38 patients+ 1 more class in this area
Metabolism & gastrointestinal
10%SGLT2 inhibitor7%Jardiance67%Farxiga33%Part D≥56 patientsPotassium supplement3%Potassium Chloride78%Klor-Con M2022%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The STAT-MI (ST-Segment Analysis Using Wireless Technology in Acute Myocardial Infarction) Trial Improves Outcomes
JACC: Cardiovascular Interventions
2011 - Treatment of Heart Failure With Preserved Ejection Fraction: Have We Been Pursuing the Wrong Paradigm?
Mayo Clinic Proceedings
2011 - Optimizing primary PCI beyond “door to intervention time”—are we there yet?
Cardiovascular revascularization medicine
2010
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”